Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 30, 2007

Astellas Licenses Regeneron’s mAb Technology in a Deal Potentially Worth $120M

  • Astellas Pharma will utilize Regeneron Pharmaceuticals’ technology in its research to discover human mAb product candidates.

    Under the terms of the nonexclusive license deal for VelocImmune, Astellas will pay $20 million upfront and will make up to five additional annual payments of $20 million per year. It retains the ability to terminate the agreement after making the first three payments. Upon commercialization of any antibody products discovered utilizing VelocImmune, Astellas will pay a mid-to-single digit royalty on sales.

    Regeneron says its VelocImmune technology offers the potential to increase the speed and efficiency of discovering fully human therapeutic mAbs. The VelocImmune platform generates mAbs to address clinically relevant targets of therapeutic interest.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »